2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 81

Transitions Among Disease Activity States: Estimates and Models of Covariate Associations
Abstract Number: 371

Treat-to-Target Strategy Aiming At Achievement of Structural and Functional Remission in Patients with Active Elderly-Onset Rheumatoid Arthritis
Abstract Number: 384

Treating Rheumatoid Arthritis to Target: A Canadian Patient Survey
Abstract Number: 284

Treatment and Outcome of ANCA-Associated Vasculitis in Children: A Pilot Study
Abstract Number: L14

Treatment of Diffuse Systemic Sclerosis Patients with Anti-Transforming Growth Factor-Beta, Fresolimumab, Inhibits Transforming Growth Factor-Beta-Regulated Gene Expression in Skin and Is Associated with a Rapid Decline in Skin Score
Abstract Number: 2231

Treatment of Psoriatic Arthritis with Tumour Necrosis Factor á Antagonists Successfully Maintains Work Capacity: 2 Year Results of a Prospective Cohort Study
Abstract Number: 1656

Treatment of Systemic Necrotizing Vasculitides in Patients ≥65 Years Old: Results of the Multicenter Randomized Cortage Trial
Abstract Number: 1559

Treatment Outcomes From a Nurse-Led Rheumatology Clinic in Monitoring of anti-TNF Therapy – a Randomised Controlled Trial
Abstract Number: 2045

Treatment Patterns and Monitoring of Serum Uric Acid Levels in a Large Cohort of Gout Patients in the United States: Is There Room for Improvement?
Abstract Number: 1840

Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated On Non-Biologic Disease-Modifying Anti-Rheumatic Drugs
Abstract Number: 1976

Treatment Satisfaction in Postmenopausal Women Previously Treated with Bisphosphonates Who Transitioned to Denosumab Vs Ibandronate Therapy in an Open-Label Study
Abstract Number: 335

Treatment with Bgp-15, a Novel Insulin Sensitizer Attenuates Collagen-Induced Arthritis in DBA/1 Mice
Abstract Number: 73

Trends in 21^stcentury Health Care Utilization in a Rheumatoid Arthritis Cohort Compared to the General Population
Abstract Number: 395

Trends in Disease Activity, Response and Remission Rates in Rheumatoid Arthritis During the Last Decade: Results From the NOR-DMARD Register
Abstract Number: 1349

Trends in Incidence and Clinical Features of Ankylosing Spondylitis in Olmsted County (1980-2009): A Population Based Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].